3-(6-methyl-1H-indol-2-yl)-N-3-pyrrolidinyl-1H-Indazol-5-amine | 1294514-33-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 英文名称: 3-(6-methyl-1H-indol-2-yl)-N-3-pyrrolidinyl-1H-Indazol-5-amine
• 英文别名: 3-(6-methyl-1H-indol-2-yl)-N-pyrrolidin-3-yl-1H-indazol-5-amine
• CAS: 1294514-33-2
• 化学式: C₂₀H₂₁N₅
• 分子量: 331.42
• InChiKey: LONFMYCCPGGOAF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  25
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  68.5
• 氢给体数：
  4
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  3-碘-5-硝基-1H-吲唑 在 4-二甲氨基吡啶 、 1,1'-bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane complex 、 palladium 10% on activated carbon 、 氢气 、 三乙酰氧基硼氢化钠 、 caesium carbonate 、 溶剂黄146 、 三乙胺 、 三氟乙酸 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 反应 20.5h， 生成 3-(6-methyl-1H-indol-2-yl)-N-3-pyrrolidinyl-1H-Indazol-5-amine
  参考文献：
  名称：

  Optimisation of ITK inhibitors through successive iterative design cycles

  摘要：

  Based on a hit cluster of compounds inhibiting interleukin-2 inducible T-cell kinase (ITK) in the submicromolar range a series of ITK inhibitor libraries were synthesized. Through iterative design cycles including kinase crystal structure information, indolylindazole libraries were identified which showed low nanomolar activity in enzymatic and cellular assays. The potential of these novel lead series was confirmed through in vivo tests in an anti-CD3-IL2 mouse model. The intravenous administration of highly potent ITK inhibitor 11o resulted in dose-dependent, efficient suppression of IL-2. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.01.035

文献信息

• METHODS OF TREATING FIBROSIS
  申请人：Pharmacyclics LLC

  公开号：US20160199376A1

  公开（公告）日：2016-07-14

  Disclosed are methods of treating fibrosis in a patient, comprising administering to a patient in need thereof a therapeutically effective amount of an ACK inhibitor (e.g., a BTK inhibitor, such as for example an irreversible BTK inhibitor, such as for example, ibrutinib).

  本发明涉及一种治疗患者纤维化的方法，包括向需要治疗的患者施用治疗有效量的ACK抑制剂（例如，BTK抑制剂，例如不可逆的BTK抑制剂，例如ibrutinib）。
• Methods for treating B cell proliferative disorders
  申请人：Cornell University

  公开号：US10314842B2

  公开（公告）日：2019-06-11

  Described herein are methods for treating B cell proliferative disorders, in an individual in need thereof. The methods include administering to an individual in need thereof a Btk inhibitor (e.g., ibrutinib), in combination with a CDK4 inhibitor (e.g., palbociclib).

  本文描述了治疗有需要的个体的B细胞增殖性疾病的方法。这些方法包括向有需要的个体施用 Btk 抑制剂（如 ibrutinib）与 CDK4 抑制剂（如 palbociclib）。
• Methods of treating and preventing graft versus host disease
  申请人：Pharmacyclics LLC

  公开号：US10463668B2

  公开（公告）日：2019-11-05

  Described herein are methods for treating and preventing graft versus host disease using ACK inhibitors. The methods include administering to an individual in need thereof an ACK inhibitor such as ibrutinib for treating and preventing graft versus host disease.

  本文描述了使用ACK抑制剂治疗和预防移植物抗宿主疾病的方法。这些方法包括向有需要的个体施用ACK抑制剂，如伊布替尼，以治疗和预防移植物抗宿主疾病。
• TREATMENT USING BRUTON'S TYROSINE KINASE INHIBITORS AND IMMUNOTHERAPY
  申请人：Pharmacyclics, Inc.

  公开号：US20150118222A1

  公开（公告）日：2015-04-30

  Combinations of Bruton's tyrosine kinase (Btk) inhibitors, e.g., 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, with immunotherapy are provided. Also provided are methods of treating cancers, and autoimmune disorders by administering combinations of Bruton's tyrosine kinase (Btk) inhibitors, e.g., 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, and an immune checkpoint inhibitor.
• METHODS OF TREATING AND PREVENTING GRAFT VERSUS HOST DISEASE
  申请人：PHARMACYCLICS, INC.

  公开号：US20150118209A1

  公开（公告）日：2015-04-30

  Described herein are methods for treating and preventing graft versus host disease using ACK inhibitors. The methods include administering to an individual in need thereof an ACK inhibitor such as ibrutinib for treating and preventing graft versus host disease.